Myelodysplastic syndromes (MDS) are blood cancers that reduce healthy blood cell production, leading to anemia, bleeding, fatigue, and frequent infections. Treatments target the affected blood counts, ...

Myelodysplastic syndromes (MDS) and autoimmune conditions can overlap, and each may raise the risk of the other. Up to 30% of people with MDS also have an autoimmune disorder. Autoimmune conditions ...

Rytelo (imetelstat) is a medicine used to treat myelodysplastic syndromes (MDS). MDS is a rare group of disorders that affect your blood cells. Most people who get MDS are 65 years of age or older, ...

Successful Management of Neutropenic Sepsis Is Key to Better Survival of Patients With Blood Cancer in Sri Lanka: Real-World Data From the Resource-Limited Setting Myelodysplastic syndromes (MDS) ...

Bexmarilimab and Vidaza achieved high response rates in higher-risk myelodysplastic syndrome, meeting the phase 2 BEXMAB trial's primary endpoint. The treatment demonstrated a 63% objective response ...

Study findings provide new tools to assess treatment preferences when using hypomethylating agents in myelodysplastic syndromes (MDS). The study aimed to develop the TPMQ for clinicians (mTPMQ), ...